The goal of this randomized clinical trial is to determine if administration of Exparel via local infiltration for medial patellofemoral ligament (MPFL) reconstruction procedures in pediatric orthopaedic sports medicine patients provides significant pain relief and decreased narcotic use. The main questions it aims to answer are:
* Does Exparel significantly reduce Visual Analog Scale (VAS) pain scores and pain levels up to one week postoperatively?
* Does Exparel significantly decrease narcotic use (number of pills taken) up to one week postoperatively?
Researchers will compare the pain outcomes and narcotic use of patients who receive Exparel and Marcaine via local infiltration to those of patients who receive only Marcaine via local infiltration for their MPFL reconstruction surgery. The goal is to understand if there is a significant difference in patient pain outcomes and narcotic use outside the first 24 hours postoperatively.
Participants will:
* receive either Exparel + Marcaine intraoperatively or Marcaine only intraoperatively during their MPFL reconstruction surgery
* receive and complete questionnaires at postoperative days 1, 4, and 7 regarding their pain scores, levels, and outcomes, effective pain treatments, overall pain interference, narcotic use (number of pills taken), and overall pain treatment satisfaction
* receive and complete secondary outcome measures of functional and psychological outcomes regarding their MPFL reconstruction surgery at postoperative day 1

开始日期2024-12-01

申办/合作机构

Texas Scottish Rite Hospital for Children

ChiCTR2400088194 / Suspended早期临床1期IIT

Study on the individualised treatment of patients with shoulder and knee joint sports injuries based on the development of intelligent equipment and remote exercise rehabilitation system

开始日期2024-09-01

申办/合作机构-

NCT06559137 / Not yet recruiting临床2期IIT

Prospective Evaluation of Post-operative Pain Management Using Peripheral Nerve Blocks in the Pediatric Population

The goal of this randomized clinical trial is to determine if single-shot ropivacaine peripheral nerve blocks (PNB - perineural injections) for anterior cruciate ligament (ACL) reconstruction procedures in pediatric orthopaedic sports medicine patients provides significant pain relief and decreased narcotic use. The main questions it aims to answer are:
* Does ropivacaine significantly reduce Visual Analog Scale (VAS) pain scores and pain levels up to one week postoperatively?
* Does ropivacaine significantly decrease narcotic use (number of pills taken) up to one week postoperatively?
Researchers will compare the pain outcomes and narcotic use of participants who receive a single-shot ropivacaine peripheral nerve block to those of participants who do not receive a single-shot ropivacaine peripheral nerve block for their ACL reconstruction surgery. The goal is to understand if there is a significant difference in participant pain outcomes and narcotic use outside the first 24 hours postoperatively.
Participants will:
* receive either a single-shot ropivacaine peripheral nerve block intraoperatively or no peripheral nerve block during their ACL Quadriceps tendon graft or bone patellar tendon bone graft reconstruction surgery.
* receive and complete questionnaires at postoperative days 1, 4, and 7 regarding their pain scores, levels, and outcomes, effective pain treatments, overall pain interference, narcotic use (number of pills taken), and overall pain treatment satisfaction
* receive and complete secondary outcome measures of functional and psychological outcomes regarding their ACL reconstruction surgery at postoperative day 1

开始日期2024-09-01

申办/合作机构

Texas Scottish Rite Hospital for Children

100 项与运动损伤相关的临床结果

登录后查看更多信息

100 项与运动损伤相关的转化医学

登录后查看更多信息

0 项与运动损伤相关的专利（医药）

登录后查看更多信息

5,182

项与运动损伤相关的文献（医药）

2024-12-01·Regenerative Therapy

Comparison of bioactive substances in novel-developed freeze-dried platelet-rich plasma (PRP) and activated normal PRP, and investigation of bioactive substance levels after long-term storage

Article

作者: Nakajima, Ryosuke ; Uchino, Sayuri ; Wakayama, Takanori ; Yamamoto, Nanako ; Momoi, Yasumasa ; Ishijima, Muneaki ; Kobayashi, Yohei ; Saita, Yoshitomo

IntroductionIn recent years, biotherapy in orthopedics has become widespread, and platelet-rich plasma (PRP) has been readily used to treat sports injuries and osteoarthritis. Production of freeze-dried PRP (PRP-FD) results in PRP that is in powder form, allowing it to be stored for long periods at room temperature. Using this technology, we have developed Valuable Platelet-Derived Factor Concentrate Freeze Dry (VFD). However, whether VFD contains sufficient levels of bioactive substances (BS) remains unknown and retains the same levels of BS during long-term storage. In this study, we examined whether VFD contains sufficient amounts of BS and whether they retain these BS levels during long-term storage.MethodsPeripheral blood was collected from 10 healthy men (mean ± SD: 46.5 ± 15 years old) and various BS, including transforming growth factor β (TGF-β), basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), tissue inhibitors of metalloproteinases-1 (TIMP-1), interleukin-1 receptor antagonist (IL-1ra), matrix metallopeptidase-9 (MMP-9), and interleukin-6 (IL-6), were compared between VFD and normal PRP samples, including both leukocyte-rich PRP (LR-PRP) and leukocyte-poor PRP (LP-PRP). VFD was prepared using two rounds of centrifugation. LP-PRP and LR-PRP were activated by freezing and thawing before measurement. To evaluate the effects of long-term storage, the BS of VFD purified from five professional football players was compared between baseline and 1 year after storage.ResultsIn terms of the growth factors, the TGF-β and EGF levels were higher in LR-PRP than in VFD and LP-PRP (p < 0.05), while the bFGF levels were higher in VFD than in the LR-PRP and LP-PRP groups (p < 0.01). In terms of anti-inflammatory cytokines, the TIMP-1 level was lower in VFD than that in the other groups (p < 0.01), whereas the IL-1ra levels were higher in VFD than those in LP-PRP (p < 0.05) and lower than those in LR-PRP (p < 0.01). In terms of inflammatory enzymes and cytokines, the IL-1ra level was higher in VFD than that in LP-PRP (p < 0.05) and lower than that in LR-PRP (p < 0.01), whereas the IL-6 levels did not differ among the groups. Furthermore, the TGF-β, bFGF, TIMP-1, and IL-1ra levels were 5.61 → 3.38 (x10³ pg/μL), 61.0 → 63.0 (pg/μL), 3.4 → 2.7 (x10⁵ pg/μL), and 14.9 → 14.5 (x10³ pg/μL) at baseline and 1 year later, respectively. No significant differences in the BS levels were observed between baseline and 1 year after storage.ConclusionsThe VFD samples prepared in this study exhibited higher levels of anti-inflammatory cytokines than LP-PRP and contained growth factor levels similar to LP-PRP and LR-PRP. In addition, the BS levels in VFD samples were maintained after one year of storage. These results suggest that VFD can be prepared and stored and may serve as a novel treatment strategy for sports injuries in high-risk groups, such as athletes.

2024-12-01·Foot and Ankle Clinics

Lesser Metatarsophalangeal Joint Instability

Review

作者: Nery, Caio ; Baumfeld, Daniel

Lesser metatarsophalangeal joint plantar plate degeneration and tear typically presents as an attritional pattern of capsuloligamentous deficiency in middle-aged patients or sports-related chronic injuries. Knowledge of the anatomy, pathophysiological basis, common patterns, grading and classification of these injuries, and indications for surgery will aid imaging interpretation in the preoperative setting. The acuity and extent of injury, tissue quality, and functional requirements of the patient influence clinical decision-making with respect to surgical management. This article provides an overview of the open surgical treatment alternatives and the most used techniques to solve instability of the metatarsophalangeal joints.

2024-12-01·The Journal of Knee Surgery

Survey Results Concerning Current Trends in Meniscus Repair Indications and Preferences from Members of the Pediatric Research in Sports Medicine (PRiSM) Society

Article

作者: Pace, James Lee ; Huang, Rong ; Pace, J Lee ; Schlechter, John A. ; Haus, Brian ; Schlechter, John

AbstractMeniscus repair has increased in frequency, especially among surgeons who focus on youth sports injuries. The aim of this study was to determine current trends in meniscus repair among a specific subset of meniscus repair surgeons. A cross-sectional survey utilizing several clinical vignettes was administered to orthopaedic surgeon members of the Pediatric Research in Sports Medicine (PRiSM) Society to investigate surgeon experience and training, number of meniscus repair procedures performed, and surgical and rehabilitation preferences. A statistical analysis of the responses was performed to determine associations between years in practice or type of fellowship training and the number of meniscus repair procedures performed, surgical indications, and rehabilitation preferences. The response rate to various questions ranged from 61.5 (59/96) to 63.5% (61/96). In all vignettes, a majority favored repair as well as some degree of weight-bearing and range-of-motion restrictions. Surgeons who had been in practice for 6 to 10 years performed significantly more meniscus repairs per year than those who had been in practice for greater than 20 years (p = 0.009) and those who had been in practice for 0 to 5 years (p = 0.05). Surgeons who had been in practice for greater than 20 years performed a significantly higher percentage of meniscectomies relative to meniscus repairs, compared with those in practice for 0 to 5 years (p = 0.002) or 6 to 10 years (p = 0.0003). When surgeons were grouped into those with less than 10 years of experience and those with greater than 10 years of experience, the former group performed a significantly higher number of meniscus repairs relative to meniscectomies than the latter group of surgeons (p < 0.0001). Less experienced surgeons are more likely to perform meniscus repair than meniscectomy, but all surgeons surveyed had a general preference for repair in all clinical vignettes. Repair technique preferences as well as rehabilitation protocols varied widely among surgeons.

235

项与运动损伤相关的新闻（医药）

2024-10-16

·PRNewswire

Biocomposites invests in InfectoTest GmbH - developers of a bacterial-specific point-of-care test for periprosthetic joint infection (PJI)

InfectoSynovia is being developed to provide a high-accuracy bedside test that can diagnose PJI in less than five minutes It is based on InfectoTest's ability to detect the infection in tiny quantities of synovial fluid using a unique method of electrochemical analysis The investment signifies Biocomposites' ongoing commitment to providing products for the management of infection in bone and soft tissue KEELE, England, Oct. 16, 2024 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces that it has taken a minority-share interest in InfectoTest GmbH (InfectoTest), a biomedical company based in Berlin that is developing innovative point-of-care systems for the diagnosis of infectious diseases. One of InfectoTest's lead products in development is InfectoSynovia, a rapid and high-accuracy test that will detect a periprosthetic joint infection (PJI) in less than five minutes. PJI is a major problem across the world which is growing as the number of joint replacements increases due to ageing populations. In the US alone, the number of hip and knee arthroplasties is expected to quadruple over the next 10 to 20 years. PJI affects more than two percent of these patients and is now the main reason for revision arthroplasty.[i] [ii] Rapid and accurate diagnosis of PJI is essential to ensuring the patient receives the most appropriate surgical or antimicrobial treatment plan. InfectoSynovia aims to dramatically reduce the diagnosis time to less than five minutes and provide outstanding sensitivity and specificity, using a sample as small as 50 microliters (µl) of synovial fluid. Thanks to InfectoTest's unique method of electrochemical analysis, which is aided by software that can help give precise interpretation of results, InfectoSynovia will be capable of detecting low grade and culture-negative infections. Michael Harris, Chief Executive Officer of Biocomposites, said: "Periprosthetic joint infection is a large and growing problem worldwide. Quickly and accurately pinpointing the bacteria that cause each infection is essential if patients are to receive the best care and maximise their chances of full recovery. "Our investment in InfectoTest GmbH, reaffirms our commitment to providing and investing in a comprehensive range of products for the management of infection in bone and soft tissue." Svetlana Karbysheva, MD, PhD., Managing Director of InfectoTest, added: "Our InfectoSynovia test has the potential to revolutionise the diagnosis of periprosthetic joint infection. With the backing of Biocomposites, which has deep expertise in the management of infection in bone and soft tissue, and a significant global distribution network, InfectoTest will now be able to develop this essential test faster and bring it to clinicians and their patients sooner." About Biocomposites Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, South America, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds and specialty polymers for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry and sports injuries. Biocomposites products are now used in over 1 million procedures per annum and sold in more than 100 countries around the world. Please visit biocomposites.com to learn more. About InfectoTest InfectoTest GmbH is a biomedical company that develops innovative point-of-care diagnostic systems for the diagnosis of infectious diseases. Our mission is to improve the diagnostic process, in order to bring the most appropriate therapy to patients as soon as possible. [i] [ii] SOURCE Biocomposites WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

诊断试剂

2024-10-12

·华森制药

世界关节炎日，关节痛一定是关节炎吗？预防关节病要趁早

2024年10月12日，是第28个“世界骨关节炎日（WAD）”，旨在提高公众对关节炎的认识，强调对关节炎的早预防、早诊断、早治疗的重要性，防范于未然。关节炎是世界公认的头号致残性疾病，根据世界卫生组织发布的数据，全球骨关节炎患病人数已超过5亿，国家卫生健康委发布的数据显示，我国骨关节炎的总患病率达15%，保守估计患者超过1亿。骨关节炎有“三高” 严重时可导致残疾专家介绍，骨关节炎有“三高”的特点，具体是哪“三高”呢？国家卫生健康委加速康复外科专家委员会骨科专家组副组长裴福兴：骨关节炎有三高，第一高是发病率高，骨关节炎在40岁以上的人群当中发病率在46%，在60岁以上的人群当中发病率达到62%。第二个方面就是骨关节炎致残率高，第三高也就是医疗费用高。专家表示，关节疼痛是骨关节炎最常见的临床表现。初期为轻度或中度间断性隐痛，休息后好转，活动后加重；重度骨关节炎可以出现持续性疼痛或夜间痛。关节局部可有压痛，尤其是在关节肿胀时，到了晚期关节活动受限加重，最终导致残疾。关节痛一定是关节炎吗？关节痛不一定是关节炎。关节痛的原因多种多样，如运动损伤、关节退行性病变、骨发育异常等。关节炎的本质在于局部炎症，即红肿热痛。由于关节局部炎症的存在而出现关节疼痛和局部压痛外，还会表现出局部肿胀、晨僵、活动受限、局部皮温升高和皮肤发红等。引起关节炎的原因可以是感染、自身免疫性疾病或是肿瘤等。关节炎一般从30岁开始发生，随着年龄增大，逐渐出现如下症状： ➤疼痛：开始为钝痛，酸胀感，继而发展成针刺样痛，活动受限。 ➤肿胀，畸形（“O”型腿“X”型腿）、关节僵直、功能障碍，严重时出现红、肿、热、痛等症状。如果出现上述典型症状，需要及时就诊，通过专业检查进一步明确自己是否患有关节炎。关节炎都是冻出来的吗？其实，关节炎真的不是“冻”出来的。阴冷天气本身并不会引起或者加重骨关节炎，只是会使关节炎的症状更明显。关节炎发生的原因多种多样，可能是运动保护不当导致，年老、肥胖、活动量较少的人，也会出现慢性膝关节疼痛。而天气变冷后之所以会感觉更疼，很可能是因为在低温情况下，导致疼痛的前列腺素在膝关节内积累了起来，让疼痛更明显。生活中如何预防关节炎：保持健康体重：减轻体重可减轻膝关节的承重压力，降低患病风险。合理运动：选择适合自己的运动方式，避免剧烈运动和长时间站立或行走。注意保暖：寒冷天气时注意保暖，避免膝关节受凉。定期体检：定期进行膝关节检查，及时发现并治疗关节损伤和疾病。华森严品森活氨糖软骨素钙胶囊，富含氨基葡萄糖盐酸盐、硫酸软骨素与钙，额外添加葛根及姜黄精华，中西结合，增加骨密度，多效呵护骨关节，行动更灵活，生活更年轻。点击以下图片即可进入华森大药房网上商城

疫苗

2024-10-11

·GlobeNewswire-Health Care

Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002

Oct. 08, 2024 -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments for brain-related health conditions, has completed a key study for their new concussion drug, ONP-002. This drug is designed to be delivered through the nose, which could help it reach the brain quickly after a head injury. The recent study shows that the drug successfully targets areas inside the nose that are connected to the brain. This makes it more likely to reach and treat the brain after a concussion. Intranasal casting studies are valued by the FDA for pharmaceuticals delivered via the nasal passage and accept such studies in FDA submissions. Oragenics is now preparing to move forward with human testing (Phase II) in patients who come to the emergency room with a concussion, aiming to give the first dose of the drug within 8 hours of the injury. "In preparing for our Phase II study, we wanted to study whether our nasal spray device would give ONP-002 an increased chance of reaching the brain quickly after a concussion. The study results are promising, as they show the drug targets areas in the nose directly linked to the brain. This should increase the chances of the drug being effective in treating concussion and reduces the likelihood of it being swallowed, which is another encouraging sign," said Michael Redmond, President of Oragenics. In this study, ONP-002 was tested using a special nasal spray device. The goal of intranasal casting studies is to identify where the drug lands inside an anatomical model of the interior nose that is made from cast metal (AINI). The model is standard for intranasal drug delivery and is accepted by the FDA as a surrogate for the actual nasal passage. The results were promising, showing that the drug spreads well in the areas of the nose where it can be quickly absorbed into the brain. This makes it a strong candidate for potentially helping people recover from concussions. Concussions are a common problem, with around 69 million people affected every year. Many concussions happen due to falls, car accidents, or sports injuries, and long-term symptoms can develop in up to 20% of patients. Currently, there is no pharmaceutical treatment for concussions, which is why Oragenics' work is so important. Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com. The FDA values studies on nasal drug delivery systems and accepts them in submissions for pharmaceuticals that use the nasal passage. These studies are critical for assessing the bioavailability and bioequivalence of drugs, particularly nasal aerosols and sprays. The FDA's guidance on bioavailability and bioequivalence emphasizes the use of in vitro and in silico methods (like computational simulations) to assess how drugs are deposited and distributed within the nasal cavity. These methods help ensure that both new drug applications (NDAs) and abbreviated new drug applications (ANDAs) meet regulatory requirements. Reference Links: Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. Computational Simulations Shed Light on Factors Affecting Nasal Spray Distribution. The content above comes from the network. if any infringement, please contact us to modify.